Obesity Surgery

, Volume 19, Issue 9, pp 1297–1303 | Cite as

The Surgical Treatment of Type II Diabetes Mellitus: Changes in HOMA Insulin Resistance in the First Year Following Laparoscopic Roux-en-Y Gastric Bypass (LRYGB) and Laparoscopic Adjustable Gastric Banding (LAGB)

  • Garth H. Ballantyne
  • Annette Wasielewski
  • John K. SaundersEmail author
Research Clinical



Bariatric operations significantly improve glucose metabolism, decrease insulin resistance, and lead to clinical resolution of type II diabetes mellitus in many patients. The mechanisms that achieve these clinical outcomes, however, remain ill defined. Moreover, the relative impact of various operations on insulin resistance remains vigorously contested. Consequently, the purpose of this study was to compare directly the impact of laparoscopic Roux-en-Y gastric bypass (LRYGB) and laparoscopic adjustable gastric banding (LAGB) on hemoglobin A1c (HbA1c) levels and insulin resistance in comparable groups of morbidly obese patients.


Data were entered prospectively into our bariatric surgery database and reviewed retrospectively. Patients selected operations. Principle outcome variables were percent excess weight loss (%EWL), HbA1c, and homeostatic model assessment for insulin resistance (HOMA IR).


The number of follow-up visits for 111 LAGB patients was 263 with a median of 162 days (17–1,016) and 291 follow-up visits for 104 LRYGB patients for a median of 150 days (8–1,191). Preoperative height, weight, body mass index, age, sex, race, comorbidities, fasting glucose, insulin, HbA1c, and HOMA IR were similar for both groups. In particular, the number of patients who were diabetics and those receiving insulin and other hypoglycemic agents were similar among the two groups. The LAGB patients lost significantly less weight than the LRYGB patients (24.6% compared to 44.0% EWL). LAGB reduced HbA1c from 5.8% (2–13.8) to 5.6% (0.3–12.3). LRYGB reduced HbA1c from 5.9% (2.0–12.3) to 5.4% (0.1–9.8). LAGB reduced HOMA IR from 3.6 (0.8–39.2) to 2.3 (0–55) and LRYGB reduced HOMA IR from 4.4 (0.6–56.5) to 1.4 (0.3–15.2). Postoperative HOMA IR correlated best with %EWL. Indeed, regression equations were essentially identical for LAGB and LRYGB for drop in %EWL versus postoperative HOMA IR.


Percent excess weight loss significantly predicts postoperative insulin resistance (HOMA IR) during the first year following both LRYGB and LAGB.


Bariatric surgery Weight loss surgery Laparoscopic gastric bypass Laparoscopic adjustable gastric banding Type II diabetes mellitus Insulin resistance Hemoglobin A1c HOMA IR Morbid obesity 


  1. 1.
    Gumbs A, Modlin IM, Ballantyne GH. Changes in insulin resistance following bariatric surgery: role of caloric restriction and weight loss. Obes Surg. 2005;15(4):462–73.CrossRefGoogle Scholar
  2. 2.
    Ballantyne GH. Changes in insulin resistance following bariatric surgery and the adipoinsular axis: role of adipocystokines, leptin, adiponectin and resistin. Obes Surg. 2005;15(5):692–9.CrossRefGoogle Scholar
  3. 3.
    Sanderson I, Deitel M, Bojm MA. Handling of glucose and insulin response before and after weight loss with JI bypass. JPEN. 1983;7:274–6.CrossRefGoogle Scholar
  4. 4.
    Deitel M, Sidhu PS, Stone E. Effect of vertical banded gastroplasty on diabetes in the morbidly obese. Obes Surg. 1991;1:113–4. (Abstract).Google Scholar
  5. 5.
    Jensen K, Mason EE. Changes in the postoperative hypoglycemic and antihypertensive medication requirements in morbidly obese diabetic patients after vertical banded gastroplasty. Obes Surg. 1991;1:114. (abstract).Google Scholar
  6. 6.
    Pories WJ, MacDonald KG Jr, Flickinger EG, et al. Is type II diabetes mellitus (NIDDM) a surgical disease? Ann Surg. 1992;215(6):633–42. discussion 643.CrossRefGoogle Scholar
  7. 7.
    Scopinaro N, Adami GF, Marinari GM, et al. Biliopancreatic diversion. World J Surg. 1998;22(9):936–46.CrossRefGoogle Scholar
  8. 8.
    Dixon JB, O'Brien PE. Changes in comorbidities and improvements in quality of life after LAP-BAND placement. Am J Surg. 2002;184(6B):51S–4S.CrossRefGoogle Scholar
  9. 9.
    Silecchia G, Boru C, Pecchia A, et al. Effectiveness of laparoscopic sleeve gastrectomy (first stage of biliopancreatic diversion with duodenal switch) on co-morbidities in super-obese high-risk patients. Obes Surg. 2006;16(9):1138–44.CrossRefGoogle Scholar
  10. 10.
    Dixon J, O'Brien P, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA. 2008;299(3):316–23.CrossRefGoogle Scholar
  11. 11.
    Deitel M. Glycemic control after bariatric surgery. Obes Surg. 1996;6:349–50.CrossRefGoogle Scholar
  12. 12.
    Hickey MS, Pories WJ, MacDonald KG Jr, et al. A new paradigm for type 2 diabetes mellitus: could it be a disease of the foregut? Ann Surg. 1998;227(5):637–43. discussion 643–4.CrossRefGoogle Scholar
  13. 13.
    Rubino F, Marescaux J. Effect of duodenal–jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg. 2004;239(1):12–3.CrossRefGoogle Scholar
  14. 14.
    Rubino F, Forgione A, Cummings DE, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg. 2006;244(5):741–9.CrossRefGoogle Scholar
  15. 15.
    Sirinek KR, O'Dorisio TM, Hill D, McFee AS. Hyperinsulinism, glucose-dependent insulinotropic polypeptide, and the enteroinsular axis in morbidly obese patients before and after gastric bypass. Surgery. 1986;100(4):781–7.PubMedGoogle Scholar
  16. 16.
    Scopinaro N, Marinari GM, Camerini GB, et al. Specific effects of biliopancreatic diversion on the major components of metabolic syndrome: a long-term follow-up study. Diabetes Care. 2005;28(10):2406–11.CrossRefGoogle Scholar
  17. 17.
    Ballantyne G, Farkas D, Laker S, Wasielewski A. Short term changes in insulin resistance following weight loss surgery for morbid obesity: laparoscopic adjustable gastric banding (LAGB) versus laparoscopic Roux-en-Y gastric bypass (LRYGB). Obes Surg. 2006;16(9):1189–97.CrossRefGoogle Scholar
  18. 18.
    Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–9.CrossRefGoogle Scholar
  19. 19.
    Wallace T, Levy J, Matthews D. Use and abuse of HOMA modeling. Diabetes Care. 2004;27(6):1487–95.CrossRefGoogle Scholar
  20. 20.
    Ren CJ, Fielding GA. Laparoscopic adjustable gastric banding: surgical technique. J Laparoendoscopic Adv Surg Tech A. 2003;13(4):257–63.CrossRefGoogle Scholar
  21. 21.
    Chau WY, Schmidt HJ, Davis D, et al. Patient factors impacting excess weight loss following laparoscopic adjustable gastric banding. Obes Surg. 2005;15(3):346–50.CrossRefGoogle Scholar
  22. 22.
    Oliak D, Ballantyne GH, Davies RJ, et al. Short-term results of laparoscopic gastric bypass in patients with BMI > or =60. Obes Surg. 2002;12(5):643–7.CrossRefGoogle Scholar
  23. 23.
    Oliak D, Ballantyne GH, Weber P, et al. Laparoscopic Roux-en-Y gastric bypass: defining the learning curve. Surg Endosc. 2003;17(3):405–8.CrossRefGoogle Scholar
  24. 24.
    Ponce J, Haynes B, Paynter S, et al. Effect of Lap-Band-induced weight loss on type 2 diabetes mellitus and hypertension. Obes Surg. 2004;14:1335–42.CrossRefGoogle Scholar
  25. 25.
    Lee W-J, Lee Y-C, Ser K-H, et al. Improvement of insulin resistance after obesity surgery: a comparison of gastric banding and bypass procedures. Obes Surg. 2008;18:1119–25.CrossRefGoogle Scholar
  26. 26.
    Leonetti F, Silecchia G, Iacobellis G, et al. Different plasma ghrelin levels after laparoscopic gastric bypass and adjustable gastric banding in morbid obese subjects. J Clin Endocrinol Metab. 2003;88(9):4227–31.CrossRefGoogle Scholar
  27. 27.
    Cottam DR, Atkinson J, Anderson A, et al. A case-controlled matched-pair cohort study of laparoscopic Roux-en-Y gastric bypass and Lap-Band patients in a single US center with three-year follow-up. Obes Surg. 2006;16(5):534–40.CrossRefGoogle Scholar
  28. 28.
    le Roux CW, Aylwin SJ, Batterham RL, et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg. 2006;243(1):108–14.CrossRefGoogle Scholar
  29. 29.
    Wickremesekera K, Miller G, DeSilva T, et al. Loss of insulin resistance after Roux-en-Y gastric bypass surgery; a time course study. Obes Surg. 2005;15(4):474–81.CrossRefGoogle Scholar
  30. 30.
    Laferrere B, Teixeira J, McGinty J, et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008;93(7):2479–85.CrossRefGoogle Scholar
  31. 31.
    Ballantyne GH. Peptide YY(1–36) and peptide YY(3–36): part II. Changes after gastrointestinal surgery and bariatric surgery. Obes Surg. 2006;16(6):795–803.CrossRefGoogle Scholar
  32. 32.
    Greenway SE, Greenway FL 3rd, Klein S. Effects of obesity surgery on non-insulin-dependent diabetes mellitus. Arch Surg. 2002;137(10):1109–17.CrossRefGoogle Scholar
  33. 33.
    Patriti A, Facchiano E, Sanna A, et al. The enteroinsular axis and the recovery from type 2 diabetes after bariatric surgery. Obes Surg. 2004;14:840–8.CrossRefGoogle Scholar
  34. 34.
    Ballantyne GH. Peptide YY(1–36) and peptide YY(3–36): part I. Distribution, release and actions. Obes Surg. 2006;16(5):651–8.CrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2009

Authors and Affiliations

  • Garth H. Ballantyne
    • 2
  • Annette Wasielewski
    • 2
  • John K. Saunders
    • 1
    Email author
  1. 1.Department of General SurgeryNew York UniversityNew YorkUSA
  2. 2.Section of Minimally Invasive SurgeryHackensack University Medical CenterHackensackUSA

Personalised recommendations